AramaPharm

AramaPharm is a clinical-stage biopharmaceutical company based in South Korea, focused on developing innovative therapies for liver and metabolic diseases. The company's lead candidate, Aramchol (arachidyl amido cholanoic acid), is a first-in-class, orally delivered small molecule that targets Stearoyl-CoA desaturase 1 (SCD1) to reduce liver fat and fibrosis. AramaPharm is primarily advancing Aramchol through Phase 2 and Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC). By modulating hepatic lipid metabolism, the company aims to provide effective treatments for chronic liver conditions with high unmet medical needs.